HESTER BIOSCIENCES
|
HESTER BIOSCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 22.20 | 31.30 | 46.22 | 40.47 | 34.29 |
| CEPS(Rs) | 45.07 | 57.28 | 65.90 | 56.44 | 51.81 |
| DPS(Rs) | 6.00 | 8.00 | 10.00 | 10.00 | 6.60 |
| Book NAV/Share(Rs) | 343.00 | 328.82 | 305.61 | 268.38 | 236.36 |
| Tax Rate(%) | 33.76 | 30.18 | 26.20 | 30.75 | 24.98 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.44 | 18.81 | 25.32 | 31.97 | 30.23 |
| EBIT Margin(%) | 16.97 | 18.46 | 24.30 | 26.41 | 26.57 |
| Pre Tax Margin(%) | 10.48 | 14.98 | 22.58 | 23.33 | 22.55 |
| PAT Margin (%) | 6.94 | 10.46 | 16.67 | 16.16 | 16.92 |
| Cash Profit Margin (%) | 12.58 | 18.18 | 23.67 | 22.36 | 24.05 |
| Performance Ratios | |||||
| ROA(%) | 3.18 | 4.55 | 8.11 | 8.70 | 9.04 |
| ROE(%) | 7.41 | 10.39 | 16.17 | 16.16 | 16.38 |
| ROCE(%) | 9.59 | 9.60 | 14.12 | 17.33 | 16.53 |
| Asset Turnover(x) | 0.46 | 0.44 | 0.49 | 0.54 | 0.53 |
| Sales/Fixed Asset(x) | 0.79 | 0.73 | 0.82 | 0.95 | 0.83 |
| Working Capital/Sales(x) | 2.80 | 3.40 | 2.42 | 2.14 | 2.42 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.26 | 1.37 | 1.22 | 1.06 | 1.21 |
| Receivable days | 94.77 | 91.87 | 80.50 | 91.49 | 90.92 |
| Inventory Days | 96.04 | 109.08 | 106.00 | 107.25 | 114.27 |
| Payable days | 107.38 | 113.04 | 129.73 | 174.82 | 187.68 |
| Valuation Parameters | |||||
| PER(x) | 62.57 | 48.58 | 58.75 | 47.36 | 26.98 |
| PCE(x) | 30.83 | 26.54 | 41.20 | 33.96 | 17.85 |
| Price/Book(x) | 4.05 | 4.62 | 8.88 | 7.14 | 3.91 |
| Yield(%) | 0.43 | 0.53 | 0.37 | 0.52 | 0.71 |
| EV/Net Sales(x) | 4.62 | 5.81 | 10.67 | 8.00 | 4.82 |
| EV/Core EBITDA(x) | 21.86 | 23.52 | 34.01 | 23.37 | 14.31 |
| EV/EBIT(x) | 27.17 | 31.26 | 43.55 | 30.22 | 18.16 |
| EV/CE(x) | 2.65 | 2.82 | 4.46 | 4.17 | 2.29 |
| M Cap / Sales | 3.88 | 4.86 | 9.83 | 7.61 | 4.29 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 14.45 | 13.23 | 9.65 | 16.95 | 2.92 |
| Core EBITDA Growth(%) | -2.23 | -10.80 | 0.52 | 18.74 | -17.91 |
| EBIT Growth(%) | 4.56 | -14.06 | 1.51 | 16.45 | -23.30 |
| PAT Growth(%) | -24.50 | -29.00 | 13.79 | 11.92 | -23.82 |
| EPS Growth(%) | -29.06 | -32.28 | 14.20 | 18.03 | -29.83 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.82 | 0.96 | 0.86 | 0.46 | 0.60 |
| Current Ratio(x) | 2.03 | 1.53 | 2.01 | 2.63 | 1.91 |
| Quick Ratio(x) | 1.31 | 0.96 | 1.23 | 1.62 | 1.14 |
| Interest Cover(x) | 2.62 | 5.31 | 14.16 | 8.59 | 6.61 |
| Total Debt/Mcap(x) | 0.20 | 0.21 | 0.10 | 0.06 | 0.15 |
Compare Financial Ratios of peers of HESTER BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| HESTER BIOSCIENCES | ₹2,205.0 Cr | -0.2% | 8.6% | 76.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,892.0 Cr | 3.7% | -3.2% | 46.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹166,129.0 Cr | 5.1% | 6.1% | 64% | Stock Analytics | |
| CIPLA | ₹121,231.0 Cr | 0.6% | -3.7% | 26.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,431.0 Cr | 1.9% | -3.4% | 5.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,639.9 Cr | 2.3% | -3.4% | 54% | Stock Analytics | |
HESTER BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| HESTER BIOSCIENCES | -0.2% |
8.6% |
76.1% |
| SENSEX | 0.9% |
2% |
21% |
You may also like the below Video Courses
